We collect cookies to enhance your browsing experience Learn more

Towards Healthcare

RNAi Therapeutics Market Size & Gene Silencing for Targeted Treatment

Market insights predict the global RNAi therapeutics industry will increase from USD 1.28 billion in 2024 to USD 5.11 billion by 2034, achieving a CAGR of 14.9%. In 2023, siRNA therapy dominated with a 64% market share, leading the RNA-based treatment space. Cancer remained the top focus, with oncology applications expected to stay ahead in the coming years. North America led the market, holding a 41% share, highlighting strong regional adoption and investment.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global RNAi Therapeutics Market Assessment

  • Overview
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

North America RNAi Therapeutics Market Assessment

  • Overview
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Europe RNAi Therapeutics Market Assessment

  • Overview
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Asia Pacific RNAi Therapeutics Market Assessment

  • Overview
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Latin America RNAi Therapeutics Market Assessment

  • Overview
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Middle East and Africa RNAi Therapeutics Market Assessment

  • Overview
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Company Profiles

  • Alnylam Pharmaceuticals, Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Novartis
  • Arbutus Biopharma
  • Arrowhead Pharmaceuticals
  • Novo Nordisk (Dicerna Pharmaceuticals)
  • Sirnaomics

Conclusion & Recommendations

  • Insight Code: 5115
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: March 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a dedicated market research professional with over 2 years of experience in the healthcare industry. Specializing in healthcare market research, she brings valuable expertise in analyzing market trends, evaluating industry dynamics, and providing actionable insights to help businesses stay ahead in a competitive market.

Throughout her career, Deepa has focused on delivering in-depth research on various healthcare segments, including pharmaceuticals, biotechnology, and healthcare services. She excels in identifying emerging opportunities, assessing market risks, and understanding regulatory changes that impact the healthcare sector.

Her ability to synthesize complex data and translate it into clear, concise recommendations makes her a key contributor to successful strategic decision-making. Her work helps organizations better understand consumer behavior, market demands, and the regulatory landscape, facilitating informed business strategies.

With a passion for healthcare research and a commitment to excellence, Deepa continues to provide businesses with the market intelligence they need to thrive in an increasingly complex healthcare environment. Her insights are critical for companies seeking to navigate the evolving healthcare landscape and optimize their market positioning.

FAQ's

RNAi therapeutics use small RNA molecules to target and silence specific genes involved in disease progression, offering potential therapies for various diseases, including cancer, genetic disorders, and viral infections.

North America leads the RNAi therapeutics market, with a significant presence of biopharmaceutical companies, robust research infrastructure, and supportive regulatory frameworks driving innovation and commercialization efforts.

The clinical use of RNAi therapeutics faces delivery challenges due to the susceptibility of RNA molecules to degradation by bodily nucleases, limiting stability and bioavailability. Additionally, unintended interactions with mRNA targets can cause off-target effects and potential toxicity.

National Institute of Health, World Health Organization, Food and Drug Administration, American Cancer Society.

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 465

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 465